Immediate Impact

1 by Nobel laureates 6 from Science/Nature 70 standout
Sub-graph 1 of 23

Citing Papers

Transferrin receptor targeting chimeras for membrane protein degradation
2024 StandoutNature
Natural killer cell therapies
2024 StandoutNature
2 intermediate papers

Works of Matthew J. Barth being referenced

Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20+ rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia
2015
Ofatumumab (OFA) Is a Novel Anti-CD20 Monoclonal Antibody (mAb) with Improved Anti-Tumor Activity in Vitro and in Vivo in Mantle Cell Lymphoma (MCL) Pre-Clinical Models.
2012

Author Peers

Author Last Decade Papers Cites
Matthew J. Barth 360 540 166 374 70 1.2k
Rosaria De Filippi 443 455 284 376 61 1.1k
Friederike Kreisel 358 378 202 360 61 1.4k
K. Henry 349 298 359 279 41 1.3k
Monika Prochorec‐Sobieszek 307 286 166 227 104 1.1k
E. L. Jones 384 301 106 193 81 1.2k
Jerald Z. Gong 492 397 371 259 74 1.3k
Adriana García‐Herrera 624 587 96 294 103 1.4k
Odile David 206 409 65 349 50 1.3k
Juehua Gao 318 250 264 226 59 1.1k
Csaba Bödör 358 325 359 351 105 1.2k

All Works

Loading papers...

Rankless by CCL
2026